SHARON, Pa., Oct. 18 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(Pink Sheets: NNLX), a nanobiotechnology company moving rapidly towards the
commercialization of its proprietary technologies for hydrogen generation
systems, announced today that it has signed an agreement to install a
NanoLogix hydrogen generation system using Welch Food's waste organic matter.
The NanoLogix methodology for hydrogen production is being developed for the
limitless production of hydrogen from organic containing waste waters. Once
successfully accomplished, this has the potentiality for solving the world
energy crisis through the limitless production of hydrogen from any waste
organic materials, such as sewer water, ground up garbage, etc. NanoLogix has
assembled a distinguished team of scientists and university professors to work
on this exciting project.
The NanoLogix reactor will utilize multiple proprietary methodologies for
synergistically creating a hydrogen bioreactor. The hydrogen production
method will utilize organic waste from Welch Food's waste stream.
"We are clearly excited with the opportunity to demonstrate conclusively
that the production of hydrogen is efficient, inexpensive and can meet the
increasing demand within the marketplace, both industrial and commercial,"
stated David McClelland, President of NanoLogix, Inc.
NanoLogix, Inc. www.nanologix.net is a technology application innovator of
biogas products and services designed to assist in worldwide energy
independence and reduce pollution from renewable, environmentally-friendly
energy sources. NanoLogix had also previously engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious human diseases. The Company's patents span the
identification and antibiotic sensitivity testing of 34 disease-producing
bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
(MAI), pseudomonas, and nocardia. These bacteria are cited as prominent
causes of morbidity and mortality in patients with cancer, cystic fibrosis,
and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of
apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a
method for inducing a genetically based induction of "cell suicide" in cells.
Welch's is the world's leading marketer of Concord and Niagara grape-based
products, including grape juice and jelly. The company produces a variety of
other fruit-based products, including 100% juices, juice cocktails, and drinks
in the following forms: single serve, bottled, refrigerated, and frozen and
shelf-stable concentrates. In addition, Welch's produces a number of fruit
spread products under both the Welch's and BAMA brand names. Welch's web site
can be found at www.welchs.com.
This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members of
its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by such
forward-looking statements. Important factors currently known to management
that could cause actual results to differ materially from those in forward-
statements include fluctuation of operating results, the ability to compete
successfully and the ability to complete before-mentioned transactions. The
company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results.
SOURCE NanoLogix, Inc.